Filtros de búsqueda

Lista de obras de

A 10-year clinical experience with intermittent hormonal therapy for prostate cancer

artículo científico publicado en 2003

A Statistical Approach to Determine the Optimal Duration of Post-Treatment Follow-Up: Application to Metastatic Nonseminomatous Germ Cell Tumors

artículo científico publicado en 2016

A phase II study of irinotecan in patients with advanced renal cell carcinoma

artículo científico publicado en 2003

A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma

artículo científico publicado en 2011

A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study

artículo científico publicado en 2013

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

artículo científico publicado en 2012

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3

artículo científico publicado en 2015

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial

artículo científico publicado en 2013

Abiraterone in metastatic prostate cancer without previous chemotherapy

artículo científico publicado en 2013

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

artículo científico publicado en 2017

Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen.

artículo científico publicado en 2012

Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe

artículo científico publicado en 2014

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

artículo científico publicado en 2014

Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data

artículo científico publicado en 2007

Advanced seminoma and nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.

artículo científico publicado en 2011

Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients

artículo científico publicado en 2003

Advancing therapies in metastatic castration-resistant prostate cancer

artículo científico publicado en 2018

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

artículo científico publicado en 2015

Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer

artículo científico

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

artículo científico

Association of clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) with poor prognosis: Results of the CATS database

Biennial report on genitourinary cancers

artículo científico publicado en 2016

Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary).

artículo científico publicado en 2007

Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study

artículo científico

Bone targeted therapies in metastatic castration-resistant prostate cancer

artículo científico publicado en 2013

Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.

artículo científico publicado en 2014

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

article

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies

artículo científico publicado en 2014

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

artículo científico publicado en 2017

Can a cure be achieved with taxane-based chemotherapy plus surgery in patients with primary mediastinal non-seminomatous germ cell tumors and progression or relapse despite first-line chemotherapy?

artículo científico publicado en 2010

Cancer of unknown primary (CUP).

artículo científico publicado en 2005

Carcinoma of unknown primary (CUP).

artículo científico publicado en 2008

Carcinomas of an unknown primary origin--diagnosis and treatment

artículo científico publicado en 2011

Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents

artículo científico publicado en 2016

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

artículo científico publicado en 2017

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.

artículo científico publicado en 2016

Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer

article

Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.

artículo científico publicado en 2017

Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel

artículo científico publicado en 2017

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.

artículo científico publicado en 2017

Combination Interleukin-2 and Doxorubicin in Advanced Adult Solid Tumors: Circumvention of Doxorubicin Resistance in Soft-Tissue Sarcoma?

artículo científico publicado en 1999

Combining docetaxel with estramustine: back to the future?

artículo científico publicado en 2009

Controversies in the management of clinical stage I testis cancer

artículo científico publicado en 2006

Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].

artículo científico publicado en 2017

Corrigendum to: “European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I” [Eur Urol 2008;53:478–96] and to: “European Conse

article

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, internation

artículo científico publicado en 2017

Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study

article

Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time

scientific article published on 16 September 2013

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

artículo científico publicado en 2011

Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

artículo científico publicado en 2009

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study ⬇️

artículo científico publicado el 25 de febrero de 2011

Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer

artículo científico

Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site

artículo científico publicado en 2002

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

artículo científico publicado en 2015

Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer

artículo científico publicado en 2008

EAU guidelines on testicular cancer: 2011 update

artículo científico publicado en 2011

Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors

artículo científico publicado en 2016

Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.

artículo científico publicado en 2004

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

artículo científico publicado en 2012

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy

artículo científico publicado en 2013

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomi

artículo científico publicado en 2015

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial

artículo científico publicado en 2014

Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy

artículo científico

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study

artículo científico publicado en 2018

Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial

artículo científico publicado en 2014

Enzalutamide in European and North American men participating in the AFFIRM trial

artículo científico publicado en 2014

Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial

artículo científico publicado en 2016

Enzalutamide in metastatic prostate cancer before chemotherapy

artículo científico publicado en 2014

Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

artículo científico publicado en 2015

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

scientific article published on 26 December 2007

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

artículo científico publicado en 2007

Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy

artículo científico publicado en 2017

Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma

artículo científico publicado en 2014

False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses

artículo científico publicado en 2012

Guidelines on Testicular Cancer: 2015 Update

artículo científico

High Concentration of the EBV Latent Membrane Protein 1 in Glycosphingolipid-Rich Complexes from both Epithelial and Lymphoid Cells

article

High dose chemotherapy and germ cell tumor

artículo científico publicado en 2011

High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer

artículo científico publicado en 2004

High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting

artículo científico publicado en 2015

Hypocalcaemia in patients with metastatic bone disease treated with denosumab

artículo científico publicado en 2015

Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms

artículo científico publicado en 2015

Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.

artículo científico publicado en 2015

Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

artículo científico publicado en 2015

Intra-abdominal desmoplastic small round cell tumors: CT findings and clinicopathological correlations in 13 cases.

artículo científico publicado en 2005

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

artículo científico publicado en 2014

Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome

artículo científico publicado en 2015

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

artículo científico publicado en 2017

Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer

artículo científico publicado en 2016

Managing Nonmetastatic Castration-resistant Prostate Cancer

Managing Nonmetastatic Castration-resistant Prostate Cancer

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

artículo científico

Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options

artículo científico

Natural History of Patients Presenting Biochemical Recurrence After Radical Prostatectomy: Some Good News? ⬇️

artículo científico publicado el 17 de marzo de 2011

New and emerging therapies for bone metastases in genitourinary cancers

artículo científico publicado en 2012

Nonhormone therapy for metastatic castration-resistant prostate cancer: chemotherapy, bone-targeted treatments, and others

artículo científico publicado en 2013

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

artículo científico publicado en 2015

Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer

artículo científico publicado en 2011

One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?

artículo científico publicado en 2014

Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer

artículo científico publicado en 2016

Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach

artículo científico publicado en 2008

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial

artículo científico publicado en 2015

Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial

artículo científico publicado en 2015

Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP).

artículo científico publicado en 2004

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

artículo científico publicado en 2018

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial

artículo científico publicado en 2014

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.

artículo científico publicado en 2015

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

artículo científico publicado en 2009

Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based th

artículo científico publicado en 2015

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

artículo científico publicado en 2017

Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study

artículo científico publicado en 2016

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).

artículo científico publicado en 2018

Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours

artículo científico publicado en 2016

Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies

artículo científico publicado en 2015

Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer

artículo científico publicado en 2015

Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors

artículo científico publicado en 2016

Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.

artículo científico publicado en 2003

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer

artículo científico publicado en 2014

Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology?

artículo científico publicado en 2017

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results

artículo científico publicado en 2015

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

artículo científico publicado en 2009

Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tu

artículo científico publicado en 2008

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

artículo científico publicado en 2016

Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre

artículo científico publicado en 2017

Rebuttal from authors re: Joaquim Bellmunt. Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol 2009;55:1310-2.

artículo científico publicado en 2008

Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with everolimus

artículo científico publicado en 2009

Reply to Araki et al.

artículo científico publicado en 2013

Reply to C. Ren et al

article

Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Predniso

artículo científico publicado en 2016

Reply to K. Lu.

artículo científico publicado en 2015

Role of targeted therapy in the treatment of advanced prostate cancer

artículo científico publicado en 2010

STEAP, a prostate tumor antigen, is a target of human CD8+ T cells

artículo científico publicado en 2006

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial

artículo científico publicado en 2017

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials

artículo científico publicado en 2017

Safety of available treatment options for renal cell carcinoma

artículo científico publicado en 2016

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

artículo científico publicado en 2015

Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study

article

Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.

artículo científico publicado en 2013

Sequential therapy in renal cell carcinoma

artículo científico publicado en 2009

Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies

artículo científico publicado en 2013

Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer ⬇️

artículo científico publicado el 23 de octubre de 2010

Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.

artículo científico publicado en 2016

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials

artículo científico publicado en 2012

Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer

artículo científico publicado en 2018

Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone

artículo científico publicado en 2012

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy

artículo científico

Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer

scientific article published on February 2014

Targeting continued androgen receptor signaling in prostate cancer

artículo científico publicado en 2011

The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population

artículo científico publicado en 2016

The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer

artículo científico publicado en 2012

The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer

artículo científico publicado en 2002

The emerging role of antifolates in the treatment of malignant pleural mesothelioma

artículo científico publicado en 2002

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer

artículo científico publicado en 2010

The use of estramustine phosphate in the modern management of advanced prostate cancer

scientific article published on 14 July 2011

Towards random sequencing or precision medicine in castration-resistant prostate cancer?

artículo científico publicado en 2013

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer

artículo científico publicado en 2013

Treatment for patients with unknown primary cancer and favorable prognostic factors

artículo científico publicado en 2009

Treatment of hormone-naïve metastatic prostate cancer

scientific article published on 01 September 2018

Treatment of testicular cancer

artículo científico publicado en 2013

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

artículo científico publicado en 2016

Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data

artículo científico publicado en 2013

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

artículo científico publicado en 2018

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

artículo científico publicado en 2014

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda